LIANYUNGANG, China, April 25, 2016 /PRNewswire/ -- Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced today that they have entered into a research agreement with Albert Einstein College of Medicine (Einstein) to advance cancer treatment. The multi-year cancer research agreement brings together the scientific and clinical capabilities of Einstein and Jiangsu Hengrui Medicine to develop innovative cancer therapies. The immediate goal of this research is to discover new targets and develop therapies in oncology space.

Dr. Guoqing Cao, Vice President of Jiangsu Hengrui Medicine, commented: "Einstein is a prominent medical research institute with a long track record of achievements in advancing cancer research and fighting cancer. Hengrui is very pleased to partner with Einstein to develop innovative oncology therapies. The collaboration will further strengthen Hengrui's leading position as the oncology drug developer in China."

The collaboration with Jiangsu Hengrui Medicine is the first between Einstein and a China based pharmaceutical company.

About Jiangsu Hengrui Medicine Co., Ltd.


SOURCE Jiangsu Hengrui Medicine Co., Ltd

Related Links

http://www.hrs.com.cn